These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 38179547)

  • 1. Successful Treatment with Dabrafenib/Trametinib of a Malignantly Transformed and Metastasized BRAF V600E Mutant Pleiomorphic Xanthoastrocytoma: A Case Report and Review of the Literature.
    Vermeulen E; Vander Mijnsbrugge AS; Brock S; Vaeyens F; Dirven I; Ciçek A; Marcelis W; Klein S; Bruneau M; Neyns B; Duerinck J
    Case Rep Oncol; 2024; 17(1):10-16. PubMed ID: 38179547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRAF/MEK Dual Inhibitors Therapy in Progressive and Anaplastic Pleomorphic Xanthoastrocytoma: Case Series and Literature Review.
    Kata K; Rodriguez-Quintero JC; Arevalo OD; Zhang JJ; Bhattacharjee MB; Ware C; Dono A; Riascos-Castaneda R; Tandon N; Blanco A; Esquenazi Y; Ballester LY; Amsbaugh M; Day AL; Zhu JJ
    J Natl Compr Canc Netw; 2022 Nov; 20(11):1193-1202.e6. PubMed ID: 36351333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using personalized medicine in gliomas: a genomic approach to diagnosis and overcoming treatment resistance in a case with pleomorphic xanthoastrocytoma.
    Piña Y; Fusco MJ; Macaulay RJ; Walko CM; Peguero E; Evernden BR; Smalley KS; Forsyth P
    J Neurol; 2020 Mar; 267(3):783-790. PubMed ID: 31748891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recurrent copy number alterations in low-grade and anaplastic pleomorphic xanthoastrocytoma with and without BRAF V600E mutation.
    Vaubel RA; Caron AA; Yamada S; Decker PA; Eckel Passow JE; Rodriguez FJ; Nageswara Rao AA; Lachance D; Parney I; Jenkins R; Giannini C
    Brain Pathol; 2018 Mar; 28(2):172-182. PubMed ID: 28181325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful treatment of pediatric patients with high-grade gliomas featuring leptomeningeal metastases by targeting BRAF V600E mutations with dabrafenib plus trametinib: two illustrative cases.
    Kawaguchi Y; Watanabe Y; Miyakita Y; Ohno M; Ogawa C; Takahashi M; Yanagisawa S; Mukai T; Igaki H; Sugino H; Yoshida A; Narita Y
    Int Cancer Conf J; 2024 Jul; 13(3):256-262. PubMed ID: 38962052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bevacizumab, irinotecan, temozolomide, tyrosine kinase inhibition, and MEK inhibition are effective against pleomorphic xanthoastrocytoma regardless of V600E status.
    Thompson EM; Landi D; Ashley D; Keir ST; Bigner D
    J Neurooncol; 2018 Nov; 140(2):261-268. PubMed ID: 30120661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pleomorphic xanthoastrocytoma, anaplastic pleomorphic xanthoastrocytoma, and epithelioid glioblastoma: Case series with clinical characteristics, molecular features and progression relationship.
    Lin Z; Yang R; Zheng H; Li Z; Yi G; Wu Q; Yang C; Huang G
    Clin Neurol Neurosurg; 2022 Oct; 221():107379. PubMed ID: 35932588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Redifferentiation of BRAF V600E-Mutated Radioiodine Refractory Metastatic Papillary Thyroid Cancer After Treatment With Dabrafenib and Trametinib.
    Jafri S; Yaqub A
    Cureus; 2021 Aug; 13(8):e17488. PubMed ID: 34595070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Upfront BRAF/MEK inhibitors for treatment of high-grade glioma: A case report and review of the literature.
    Arbour G; Ellezam B; Weil AG; Cayrol R; Vanan MI; Coltin H; Larouche V; Erker C; Jabado N; Perreault S
    Neurooncol Adv; 2022; 4(1):vdac174. PubMed ID: 36567957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRAF V600E, TERT, and IDH2 Mutations in Pleomorphic Xanthoastrocytoma: Observations from a Large Case-Series Study.
    Ma C; Feng R; Chen H; Hameed NUF; Aibaidula A; Song Y; Wu J
    World Neurosurg; 2018 Dec; 120():e1225-e1233. PubMed ID: 30240866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in
    Wang JR; Zafereo ME; Dadu R; Ferrarotto R; Busaidy NL; Lu C; Ahmed S; Gule-Monroe MK; Williams MD; Sturgis EM; Goepfert RP; Gross ND; Lai SY; Gunn GB; Phan J; Rosenthal DI; Fuller CD; Morrison WH; Iyer P; Cabanillas ME
    Thyroid; 2019 Aug; 29(8):1036-1043. PubMed ID: 31319771
    [No Abstract]   [Full Text] [Related]  

  • 12. Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF
    Schadendorf D; Hauschild A; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Lesimple T; Plummer R; Schachter J; Dasgupta K; Manson S; Koruth R; Mookerjee B; Kefford R; Dummer R; Kirkwood JM; Long GV
    Lancet Oncol; 2019 May; 20(5):701-710. PubMed ID: 30928620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual BRAF/MEK therapy in BRAF V600E-mutated primary brain tumors: a case series showing dramatic clinical and radiographic responses and a reduction in cutaneous toxicity.
    Bernstein A; Mrowczynski OD; Greene A; Ryan S; Chung C; Zacharia BE; Glantz M
    J Neurosurg; 2020 Dec; 133(6):1704-1709. PubMed ID: 31675726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful re-challenge of dabrafenib-trametinib combination therapy in advanced
    Xue Y; Ren Y; Yan B; Li Z; Huang C
    Ann Transl Med; 2022 Sep; 10(18):1029. PubMed ID: 36267742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interstitial lung disease associated with combination therapy of dabrafenib and trametinib in metastatic BRAF
    Zeng Q; Deng Y; Zhang L; Wang W
    Int J Clin Pharmacol Ther; 2022 May; 60(5):225-231. PubMed ID: 35072623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Case report: complete long-lasting response to multimodal third line treatment with neurosurgical resection, carmustine wafer implantation and dabrafenib plus trametinib in a
    Castelli B; Tellini M; Guidi M; Di Nicola M; Giunti L; Buccoliero AM; Censullo ML; Iacono A; Desideri I; Genitori L; Sardi I; Fonte C
    Front Oncol; 2024; 14():1359093. PubMed ID: 38774414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Promising Response to Dabrafenib Plus Trametinib in a Patient with Peritoneal Carcinomatosis from Non Small Lung Cancer Harboring
    Yagami Y; Nakahara Y; Manabe H; Yamamoto H; Otani S; Sato T; Igawa S; Kubota M; Sasaki J; Naoki K
    Onco Targets Ther; 2022; 15():1369-1374. PubMed ID: 36388158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complete response of metastatic
    Lee SJ; Song SY; Kim MK; Na HG; Bae CH; Kim YD; Choi YS
    World J Clin Cases; 2023 Sep; 11(27):6664-6669. PubMed ID: 37900238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Papillary Thyroid Cancer Differentiating Into Anaplastic Carcinoma With Near-Complete Response to Targeted Dabrafenib/Trametinib Combination Therapy.
    Kulkarni P; Hall J; Wang L; Henderson S
    Cureus; 2021 Dec; 13(12):e20693. PubMed ID: 35106230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of
    Gowda S; Sandow L; Heinrich MC
    J Gastrointest Oncol; 2024 Apr; 15(2):788-793. PubMed ID: 38756640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.